Shots:Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseasesAs per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…
